This week, we are sharing a video interview with Dr. Matthew Davids from ASH 2016 where we discuss a clinical trial that combines two targeted therapies for treating relapsed/refractory CLL, ibrutinib and TGR-1202. You can read the summary and watch the video or read the transcript here: cllsociety.org/2017/03/ash-...
TOMORROW, we'll be publishing the first 2017 issue of The CLL Tribune and marking the 2 year anniversary since our website went live! Watch for it!
WOW! Two years online.
We are all in this together.